Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.

Disclosed are novel hydroxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced synthetically or biosynthetically.

Disclosed are novel nitrated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The nitrated psilocybin derivative compounds may be chemically synthesized or biochemically synthesized in host cells.

The instant disclosure is in the field of biosciences, more particularly towards molecular and industrial biotechnology. The present disclosure relates to recombinant methanotrophic bacteria capable of synthesizing indigo from methane, a method of developing said recombinant methanotrophic bacteria, and a method of indigo biosynthesis by the recombinant methanotrophic bacteria in presence of a methane source.

Provided are methods, prokaryotic host cells, expression vectors, and kits for the production of psilocybin or an intermediate or a side product thereof. Also provided are methods, prokaryotic host cells, expression vectors, and kits for the production of norbaeocystin. In certain embodiments, the prokaryotic host cell is selected from the group consisting of Escherichia coli, Corynebacterium glutamicum, Vibrio natriegens, Bacillus subtilis, Bacillus megaterium, Escherichia coli Nissle 1917, Clostridium acetobutlyicum, Streptomyces coelicolor, Lactococcus lactis, Pseudomonas putida, Streptomyces clavuligerus, and Streptomyces venezuelae.

The present disclosure provides recombinant bacteria for production of indole-3-acetic acid (IAA). Pharmaceutical compositions and methods of treating diseases are also included.

The present disclosure provides methods for preparing β-substituted tryptophan compounds. The methods include: combining i) an unsubstituted indole or a substituted indole, ii) a β-substituted serine, and iii) a tryptophan synthase β-subunit (i.e., a TrpB); and maintaining the resulting mixture under conditions sufficient to form the β-substituted tryptophan. The TrpB contains at least one amino acid mutation which promotes formation of an amino-acrylate intermediate. New TrpB variants and new β-substituted tryptophan analogs are also described.

Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.

This disclosure relates to modified tryptophan synthase and more particularly to modified beta-subunits of tryptophan synthase. The disclosure further relates to cells expressing such modified subunits and methods of producing non-canonical amino acids.

The present disclosure provides engineered enzymes and methods for preparing tyrosine and tyrosine analogs from a donor amino acid and phenols in a single step. Also disclosed are methods to engineer enzymes having such ‘tyrosine synthase’ activity, starting from the beta-subunit of a tryptophan synthase (TrpB).